Edimer Logo


Posted Posted in Current, Healthcare, Portfolio, Venture Incubator

Edimer is a biotech company founded in 2008 and based in Cambridge US focusing on the development of innovative therapeutics for rare diseases. EDI 200 Fc-EDA1, its lead product is aimed at the treatment of X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare inherited genetic disease affecting mainly baby boys. Moreover, Fc-EDA1 is in development for Read the full article…

Covalys Logo


Posted Posted in Current, Healthcare, Portfolio, Venture Incubator

Covalys’ proprietary technology is based on unique protein tags (SNAP-, CLIP-, ACP/MCP-tags) which would greatly facilitate the purification, labeling and immobilization of proteins in their functional form, opening thus new opportunities for protein based research. Covalys’ tag technology combines specificity with high reliability, stability and a broad versatility in its applications. Covalys’ tag technolgy was Read the full article…

CeQur Logo


Posted Posted in Current, Healthcare, Portfolio, Venture Incubator

The CeQur PaQ™ insulin delivery device is intended for continuous, subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in patients requiring insulin as prescribed by a physician. The technology is reliable, the design had met high industry standards and the IP situation (patentability and freedom to operate) is Read the full article…

Cell Medica Logo

Kuur Therapeutics (form Cell Medica)

Posted Posted in Current, Healthcare, Portfolio, Venture Incubator

Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant. VI became shareholder of Cell Medica through its acquisition of Delenex Therapeutics. Delenex was a Read the full article…

Araris Logo


Posted Posted in Current, Healthcare, Portfolio, Venture Incubator

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on a on a novel antibody-drug conjugate (ADC)-linker technology. ADCs deliver for example chemotherapeutic drugs specifically to the tumor and thus enable targeted chemotherapy. The stable and defined linkage of the drug to the antibody is essential for Read the full article…

Amal Therapeutics Logo


Posted Posted in Exited, Healthcare, Portfolio, Venture Incubator

Amal Therapeutics SA is a spin-off from the University of Geneva. Amal develops KISIMA, its proprietary vaccine technology platform to progress therapeutic vaccines in oncology. KISIMA combines in one single recombinant protein a vector for targeted antigen delivery, a toll like receptor peptide agonist as adjuvant and a chimeric multi-antigenic construct as vaccine. The platform Read the full article…

Altoida Logo


Posted Posted in Current, Healthcare, Portfolio, Venture Incubator

Based on 12 years of R&D and clinical trials with more than 2500 patients, Altoida has developed complex everyday activities providing neuromotor biomarkers that can diagnose Alzheimer’s disease 5 years prior to onset with 94% accuracy using smartphones and augmented reality. Altoida’s technology will power apps that target both consumer and professionals markets. Learn more Read the full article…

Advanon Logo


Posted Posted in Current, Portfolio, Technology, Venture Incubator

Advanon is an online platform where SMEs looking for short-term financing can sell their invoices to financial Investors. Through the easy-to-use platform, SMEs can improve their cash balance instantly. Investors, on the other hand, get access to an alternative type of short-term investments. Unlike traditional factoring services that acquire all invoices from a seller Advanon is offering a flexible service as businesses can sell invoices when and as they need it.

Sequana Logo

Sequana Medical: strong interim results from RED DESERT alfapump® DSR study and business update

Posted Posted in News, Portfolio News

Ghent, Belgium – 22 October 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from the first five patients enrolled in the RED DESERT study, evaluating repeated dose treatment of alfapump DSR (Direct Sodium Removal) in diuretic-resistant heart failure patients. Sequana Medical also provides a business update.

Medlumics Logo

VI Partners co-leads investment in Medlumics’ €14M Series E round

Posted Posted in Fund news, News

Madrid, Spain, October 6th 2020:
Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide device placement and directly assess the ablation lesions in real time, announces today the closing of a €14 million Series E financing, co-led by Asabys Partners (through the fund Sabadell Asabys Health Innovation Investments), VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital. Several of the investors joining this round were investors in Endosense, a company in the same space acquired by Abbott (St. Jude Medical) in 2013 for more than USD 300 million.

Jenavalve Logo

JenaValve Technology strengthens senior leadership team in clinical affairs and operations

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer of a novel transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, today announced the appointment of two veteran medical device executives Vinny Podichetty, MD, MS as Vice President, Clinical Affairs, and Jeff Thiel as Vice President, Operations, effective immediately.